These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31504702)

  • 21. Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine.
    Khatri A; Dutta S; Dunbar M; Podsadecki T; Trinh R; Awni W; Menon R
    Antimicrob Agents Chemother; 2016 May; 60(5):2965-71. PubMed ID: 26953200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glecaprevir/Pibrentasvir: First Global Approval.
    Lamb YN
    Drugs; 2017 Oct; 77(16):1797-1804. PubMed ID: 28929412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
    Bifano M; Hwang C; Oosterhuis B; Hartstra J; Grasela D; Tiessen R; Velinova-Donga M; Kandoussi H; Sevinsky H; Bertz R
    Antivir Ther; 2013; 18(7):931-40. PubMed ID: 23963204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.
    Kosloski MP; Wang H; Pugatch D; Mensa FJ; Gane E; Lawitz E; Marbury TC; Preston RA; Kort J; Liu W
    Eur J Clin Pharmacol; 2019 Feb; 75(2):217-226. PubMed ID: 30341499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adults.
    Nehra V; Rizza SA; Temesgen Z
    Drugs Today (Barc); 2018 Jul; 54(7):407-421. PubMed ID: 30090878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.
    Peribañez-Gonzalez M; Cheinquer H; Rodrigues L; Lima MP; Álvares-da-Silva MR; Madruga J; Parise ER; Pessoa MG; Furtado J; Villanova M; Ferreira A; Mazzoleni F; Nascimento E; Silva GF; Fredrick L; Krishnan P; Burroughs M; Reuter T
    Ann Hepatol; 2021; 20():100257. PubMed ID: 32949786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.
    King JR; Menon RM
    Clin Pharmacol Drug Dev; 2017 Mar; 6(2):201-205. PubMed ID: 28263457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.
    Krishnan P; Pilot-Matias T; Schnell G; Tripathi R; Ng TI; Reisch T; Beyer J; Dekhtyar T; Irvin M; Xie W; Larsen L; Mensa FJ; Collins C
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.
    Nozaki A; Atsukawa M; Kondo C; Toyoda H; Chuma M; Nakamuta M; Uojima H; Takaguchi K; Ikeda H; Watanabe T; Ogawa S; Itokawa N; Arai T; Hiraoka A; Asano T; Fujioka S; Ikegami T; Shima T; Ogawa C; Akahane T; Shimada N; Fukunishi S; Abe H; Tsubota A; Genda T; Okubo H; Mikami S; Morishita A; Moriya A; Tani J; Tachi Y; Hotta N; Ishikawa T; Okanoue T; Tanaka Y; Kumada T; Iwakiri K; Maeda S;
    Hepatol Int; 2020 Mar; 14(2):225-238. PubMed ID: 32128704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.
    Cotter TG; Jensen DM
    Drug Des Devel Ther; 2019; 13():2565-2577. PubMed ID: 31534310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects.
    Kosloski MP; Zhao W; Marbury TC; Preston RA; Collins MG; Pugatch D; Mensa F; Kort J; Liu W
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of drug interactions with telaprevir and antiretrovirals.
    van Heeswijk RP; Beumont M; Kauffman RS; Garg V
    Antivir Ther; 2013; 18(4):553-60. PubMed ID: 23344266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment.
    Suda G; Nakai M; Sho T; Kimura M; Shimazaki T; Maehara O; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Baba M; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    Intern Med; 2019 Apr; 58(7):943-947. PubMed ID: 30568153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
    Berg T; Naumann U; Stoehr A; Sick C; John C; Teuber G; Schiffelholz W; Mauss S; Lohmann K; König B; Pangerl A; Niederau C
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1052-1059. PubMed ID: 30874328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy.
    Grebely J; Dore GJ; Alami NN; Conway B; Dillon JF; Gschwantler M; Felizarta F; Hézode C; Tomasiewicz K; Fredrick LM; Dumas EO; Mensa FJ
    Int J Drug Policy; 2019 Apr; 66():73-79. PubMed ID: 30735896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
    Khatri A; Trinh R; Zhao W; Podsadecki T; Menon R
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6244-51. PubMed ID: 27503645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection.
    Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews GV
    Hepatology; 2020 Jul; 72(1):7-18. PubMed ID: 31652357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world.
    Tempestilli M; Fabbri G; Mastrorosa I; Timelli L; Notari S; Bellagamba R; Libertone R; Lupi F; Zaccarelli M; Antinori A; Agrati C; Ammassari A
    J Antimicrob Chemother; 2018 Jan; 73(1):160-164. PubMed ID: 29106584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysis.
    Wang X; Fan X; Deng H; Zhang X; Zhang K; Li N; Han Q; Lv Y; Liu Z
    Int J Antimicrob Agents; 2019 Dec; 54(6):780-789. PubMed ID: 31284039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
    Suda G; Hasebe C; Abe M; Kurosaki M; Itakura J; Izumi N; Uchida Y; Mochida S; Haga H; Ueno Y; Abe K; Takahashi A; Ohira H; Tsukuda Y; Furuya K; Baba M; Yamamoto Y; Kobayashi T; Inoue J; Terasita K; Ohara M; Kawagishi N; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    J Gastroenterol; 2019 Jul; 54(7):641-649. PubMed ID: 30778716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.